Valneva begins phase III COVID-19 vaccine trial

By The Science Advisory Board staff writers

April 22, 2021 -- Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare trial will pit VLA2001 against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.

The U.K. trial will enroll 4,000 participants who will receive two doses of either vaccine. The primary end point of Cov-Compare will be to determine immune response two weeks after completion of a two-dose immunization schedule administered in a four-week interval.

Pending results, Valneva plans to submit the vaccine for initial approval later this year, the company stated.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.